Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2019

Open Access 01-12-2019 | Prostatectomy | Research article

Safety and effectiveness of high-power thulium laser enucleation of the prostate in patients with glands larger than 80 mL

Authors: Ching-Hsin Chang, Tzu-Ping Lin, Jung-Yao Huang

Published in: BMC Urology | Issue 1/2019

Login to get access

Abstract

Background

The efficacy of thulium laser prostate enucleation (ThuLEP) for large prostates is unclear. This study aimed to explore the expanded utility of 150–200-W ThuLEP by studying patients with a large prostate (> 80 mL).

Methods

We retrospectively reviewed records of 125 patients with large prostate glands (> 80 mL) who underwent ThuLEP performed by a single surgeon from June 2012 to June 2016. The ThuLEP data from our previous pilot study were used as the control. Operative variables, patient profiles, preoperative and postoperative urine flow rates, prostate volume, and the international prostate symptom score (IPSS) were recorded and analyzed using Student’s t-test, the z-test, and logistic regression analysis.

Results

Of 366 patients who underwent ThuLEP, 125 (34.15%) were enrolled. The ages and estimated prostate volumes were compared with those of the control. Overall, 39.2% underwent Foley placement and 4% received an anticoagulant agent preoperatively. Maximum urinary flow rates before and 3 and 12 months postoperatively were 9.93, 23.20, and 19.00 mL/s, respectively, which were generally equal to those of the control groups (P = 0.68, 0.18, 0.98, respectively). Preoperative and postoperative IPSSs were 27.09 and 7.35, respectively. The postoperative prostate-specific antigen was reduced by 85.59% in comparison to the preoperative level. The estimated prostate size was reduced by 74.17% postoperatively. The modified Clavien-Dindo classification system was used to identify the overall rate of complications, which was approximately 22.4%. The mortality rate was 0.8%.

Conclusions

High-power ThuLEP is safe and effective for patients with large prostate glands (> 80 mL). Prostate enucleation using a high-power thulium laser is feasible for patients who exhibit contraindications for surgery.
Literature
1.
Kuntz RM. Current role of lasers in the treatment of benign prostatic hyperplasia (BPH). Eur Urol. 2006;49(6):961–9.CrossRef
2.
Wilson LC, Gilling PJ, Williams A, Kennett KM, Frampton CM, Westenberg AM, Fraundorfer MR. A randomised trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years. Eur Urol. 2006;50(3):569–73.CrossRef
3.
Naspro R, Suardi N, Salonia A, Scattoni V, Guazzoni G, Colombo R, Cestari A, Briganti A, Mazzoccoli B, Rigatti P, et al. Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g: 24-month follow-up. Eur Urol. 2006;50(3):563–8.CrossRef
4.
de la Rosette JJ, Alivizatos G, Madersbacher S, Perachino M, Thomas D, Desgrandchamps F, de Wildt M. European Association of U: EAU Guidelines on benign prostatic hyperplasia (BPH). Eur Urol. 2001;40(3):256–63 discussion 264.CrossRef
5.
Committee AUAPG. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol. 2003;170(2 Pt 1):530–47.CrossRef
6.
Gilling PJ, Aho TF, Frampton CM, King CJ, Fraundorfer MR. Holmium laser enucleation of the prostate: results at 6 years. Eur Urol. 2008;53(4):744–9.CrossRef
7.
Elzayat EA, Elhilali MM. Holmium laser enucleation of the prostate (HoLEP): the endourologic alternative to open prostatectomy. Eur Urol. 2006;49(1):87–91.CrossRef
8.
Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol. 2008;53(1):160–6.CrossRef
9.
van Rij S, Gilling PJ. In 2013, holmium laser enucleation of the prostate (HoLEP) may be the new 'gold standard'. Curr Urol Rep. 2012;13(6):427–32.CrossRef
10.
EAU Guidelines. In., edn. the EAU Annual Congress Copenhagen 2018. ISBN: EAU Guidelines Office; 2018.
11.
Herrmann TR, Bach T, Imkamp F, Georgiou A, Burchardt M, Oelke M, Gross AJ. Thulium laser enucleation of the prostate (ThuLEP): transurethral anatomical prostatectomy with laser support. Introduction of a novel technique for the treatment of benign prostatic obstruction. World J Urol. 2010;28(1):45–51.CrossRef
12.
Fried NM, Murray KE. High-power thulium fiber laser ablation of urinary tissues at 1.94 microm. J Endourol. 2005;19(1):25–31.CrossRef
13.
Chung JS, Kang PM, Seo WI, Oh CK, Kim SC, Park SH, Choi JH, Yoon JH, Kang DI, Chung JI. Thulium laser (RevoLix) vaporesection versus vapoenucleation with morcellator (piranha) for the treatment of benign prostatic obstruction: a propensity-matched multicenter analysis. Int J Urol. 2014;21(11):1156–61.CrossRef
14.
Zarrabi A, Gross AJ. The evolution of lasers in urology. Ther Adv Urol. 2011;3(2):81–9.CrossRef
15.
Chang CH, Lin TP, Chang YH, Huang WJ, Lin AT, Chen KK. Vapoenucleation of the prostate using a high-power thulium laser: a one-year follow-up study. BMC Urol. 2015;15:40.CrossRef
16.
Zhang F, Shao Q, Herrmann TR, Tian Y, Zhang Y. Thulium laser versus holmium laser transurethral enucleation of the prostate: 18-month follow-up data of a single center. Urology. 2012;79(4):869–74.CrossRef
17.
Swiniarski PP, Stepien S, Dudzic W, Kesy S, Blewniewski M, Rozanski W. Thulium laser enucleation of the prostate (TmLEP) vs. transurethral resection of the prostate (TURP): evaluation of early results. Cent European J Urol. 2012;65(3):130–4.CrossRef
18.
Pearce SM, Pariser JJ, Malik RD, Famakinwa OJ, Chung DE. Outcomes following thulium vapoenucleation of large prostates. Int Braz J Urol. 2016;42(4):757–65.CrossRef
19.
Gross AJ, Netsch C, Knipper S, Holzel J, Bach T. Complications and early postoperative outcome in 1080 patients after thulium vapoenucleation of the prostate: results at a single institution. Eur Urol. 2013;63(5):859–67.CrossRef
20.
Bach T, Wolbling F, Gross AJ, Netsch C, Tauber S, Pottek T, Wulfing C, Brunken C. Prospective assessment of perioperative course in 2648 patients after surgical treatment of benign prostatic obstruction. World J Urol. 2017;35(2):285–92.CrossRef
21.
Kuntz RM, Lehrich K. Transurethral holmium laser enucleation versus transvesical open enucleation for prostate adenoma greater than 100 gm.:: a randomized prospective trial of 120 patients. J Urol. 2002;168(4 Pt 1):1465–9.CrossRef
22.
Mitropoulos D, Artibani W, Graefen M, Remzi M, Roupret M, Truss M. European Association of Urology Guidelines P: reporting and grading of complications after urologic surgical procedures: an ad hoc EAU guidelines panel assessment and recommendations. Eur Urol. 2012;61(2):341–9.CrossRef
23.
Netsch C, Tiburtius C, Bach T, Knipper S, Gross AJ. Association of prostate size and perioperative morbidity in thulium:YAG vapoenucleation of the prostate. Urol Int. 2014;93(1):22–8.CrossRef
24.
Naspro R, Gomez Sancha F, Manica M, Meneghini A, Ahyai S, Aho T, Fiori C, Vavassori I, LF DAP, Pansadoro V, et al. From "gold standard" resection to reproducible "future standard" endoscopic enucleation of the prostate: what we know about anatomical enucleation. Minerva Urol Nefrol. 2017;69(5):446–58.PubMed
25.
Rausch S, Heider T, Bedke J, Kruck S, Schwentner C, Fischer K, Stenzl A, Kalble T. Analysis of early morbidity and functional outcome of thulium: yttrium-aluminum-garnet laser enucleation for benign prostate enlargement: patient age and prostate size determine adverse surgical outcome. Urology. 2015;85(1):182–8.CrossRef
26.
Iacono F. Efficacy and safety profile of a novel technique, ThuLEP (thulium laser enucleation of the prostate) for the treatment of benign prostate hypertrophy. Our experience on 148 patients. BMC Surg. 2012;12(Suppl 1):S21.CrossRef
27.
Gross AJ, Orywal AK, Becker B, Netsch C. Five-year outcomes of thulium vapoenucleation of the prostate for symptomatic benign prostatic obstruction. World J Urol. 2017;35(10):1585–93.CrossRef
Metadata
Title
Safety and effectiveness of high-power thulium laser enucleation of the prostate in patients with glands larger than 80 mL
Authors
Ching-Hsin Chang
Tzu-Ping Lin
Jung-Yao Huang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2019
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-019-0437-9

Other articles of this Issue 1/2019

BMC Urology 1/2019 Go to the issue

Research article

Is it safe to use a ureteral access sheath in an unstented ureter?

Research article

Which is the best treatment of pediatric upper urinary tract stones among extracorporeal shockwave lithotripsy, percutaneous nephrolithotomy and retrograde intrarenal surgery: a systematic review

Research article

Comparisons of cancer detection rate and complications between transrectal and transperineal prostate biopsy approaches - a single center preliminary study

Research article

Testicular epidermoid cysts: a reevaluation

Research article

Anterior gland focal cryoablation: proof-of-concept primary prostate cancer treatment in select men with localized anterior cancers detected by multi-parametric magnetic resonance imaging

Research article

Comparison of the long-term follow-up and perioperative outcomes of partial nephrectomy and radical nephrectomy for 4 cm to 7 cm renal cell carcinoma: a systematic review and meta-analysis